Fact-checked by Grok 2 weeks ago

Trisomy

Trisomy is a form of aneuploidy characterized by the presence of three copies of a specific chromosome in the cells of an organism, rather than the normal diploid pair of two, resulting in a total of 47 chromosomes in humans instead of 46.^[1]^[2] This abnormality typically arises from nondisjunction, an error in chromosome segregation during meiosis I or II, where homologous chromosomes or sister chromatids fail to separate properly, leading to gametes with an extra chromosome that, upon fertilization, produces a trisomic zygote.^[3]^[4] In humans, most autosomal trisomies are embryonic lethal, causing spontaneous abortion in up to 25% of pregnancies, with only a few—primarily involving chromosomes 13, 18, and 21—resulting in live births, albeit with profound health consequences.^[5]^[6] The most prevalent viable trisomy is trisomy 21, also known as Down syndrome, occurring in approximately 1 in 691 live births and associated with intellectual disability, characteristic facial features, and increased risk of congenital heart defects and leukemia.^[7] Trisomy 18 (Edwards syndrome) and trisomy 13 (Patau syndrome) are rarer, with incidences of about 1 in 6,000–8,000 and 1 in 8,000–12,000 live births, respectively; both conditions involve severe multisystem anomalies, including central nervous system malformations, and carry high infant mortality rates exceeding 90% within the first year.^[8] Maternal age is a primary risk factor, as the likelihood of nondisjunction rises with advancing age due to declining oocyte quality, though the precise mechanisms remain under study.^[9] Diagnosis often occurs prenatally via noninvasive screening or invasive procedures like amniocentesis, with genetic counseling emphasizing empirical outcomes over optimistic projections uninformed by survival data.^[10] While supportive interventions exist, trisomies underscore the intolerance of human development to genomic imbalance, with no curative therapies currently available.^[11]

Genetics and Mechanisms

Definition and Terminology

Trisomy refers to the presence of three copies of a specific chromosome in a cell, rather than the normal diploid complement of two copies. This chromosomal abnormality results in an extra chromosome, leading to a total of 47 chromosomes in affected human cells instead of the typical 46.^[12]^[13] Trisomy is a subtype of aneuploidy, defined as any deviation from the euploid chromosome number, and most commonly arises from nondisjunction events during meiosis I or II, or less frequently during mitosis, where homologous chromosomes or sister chromatids fail to segregate properly.^[3]^[1] In terminology, a full or complete trisomy involves the extra chromosome across all cells of the organism, whereas mosaic trisomy describes a mixture of trisomic and euploid cells due to post-zygotic mitotic errors, potentially mitigating phenotypic severity depending on the proportion and distribution of affected cells.^[13] Partial trisomy, by contrast, entails duplication of only a segment of a chromosome, often resulting from unbalanced translocations or other structural variants rather than whole-chromosome nondisjunction.^[1] Trisomies are classified as autosomal when affecting chromosomes 1–22 or as sex chromosome trisomies when involving the X or Y chromosomes, such as in Klinefelter syndrome (47,XXY) or triple X syndrome (47,XXX).^[14] The term "trisomy" derives from the Greek "tris" (three) and "soma" (body), emphasizing the triplication of chromosomal material, and is distinct from polysomy (more than three copies) or monosomy (single copy).^[15] While viable trisomies are rare in humans due to gene dosage imbalances disrupting development, they provide critical models for studying genomic stability and gene regulation.^[11]

Molecular Causes and Origin

Trisomy results from nondisjunction, the failure of chromosomes to segregate properly during cell division, leading to gametes or cells with an abnormal number of chromosomes. In meiosis, nondisjunction occurs either in the first division (meiosis I), where homologous chromosomes fail to separate, or in the second division (meiosis II), where sister chromatids fail to disjoin, producing gametes with 24 chromosomes instead of 23.^[3] ^[16] Fertilization involving such a gamete yields a zygote with three copies of the affected chromosome, constituting the primary molecular etiology of full trisomy.^[17] This mechanism accounts for the vast majority of cases across autosomal trisomies, with empirical studies confirming its prevalence through DNA polymorphism analysis of parental and offspring samples.^[18] For trisomy 21, the most studied viable form, approximately 90% of cases trace to maternal meiotic nondisjunction, with 68-73% originating in meiosis I and the remainder in meiosis II, as determined by pericentromeric marker recombination patterns.^[19] ^[20] Paternal nondisjunction contributes only 5-10%, predominantly from meiosis I errors, lacking the pronounced age dependency seen in maternal cases.^[21] Advanced maternal age correlates strongly with risk, rising from 1 in 1,500 births at age 20 to 1 in 100 at age 40, due to prolonged arrest of oocytes in prophase I, leading to cohesin degradation, spindle assembly checkpoint weakening, and centromere defects that impair chromosome segregation.^[22] ^[23] Similar patterns hold for other autosomal trisomies like 13 and 18, though with higher lethality and less precise mechanistic data.^[24] Postzygotic mitotic nondisjunction, involving errors in anaphase due to inactivation of proteins like topoisomerase II, condensin, or separase, generates mosaic trisomy variants where only a subset of cells carry the extra chromosome.^[3] These account for 1-2% of viable trisomy 21 cases and are detectable via tissue-specific karyotyping.^[17] Robertsonian translocations, fusions of acrocentric chromosomes (e.g., 14;21), represent 3-4% of trisomy 21 origins and can be inherited or de novo, but they do not alter the core nondisjunction-driven etiology of free trisomies.^[25] De novo events predominate, with familial recurrence rare except in translocation carriers, underscoring nondisjunction's sporadic, age-linked causality over heritable factors.^[26]

Types and Prevalence

Autosomal Trisomies

Autosomal trisomies refer to the presence of an extra copy of one of the 22 non-sex chromosomes, resulting from nondisjunction during meiosis or early mitosis.^[2] These conditions disrupt gene dosage balance, leading to profound developmental abnormalities; the majority cause embryonic lethality, with most affected pregnancies ending in spontaneous abortion before 12 weeks gestation.^[11] Only trisomies of chromosomes 13, 18, and 21 yield live births at appreciable rates, though survival beyond infancy remains rare except for trisomy 21.^[2]^[27] Full trisomies of other autosomes (e.g., 1–12, 14–17, 19–20, 22) are exceptionally uncommon in live births, typically surviving only hours to days due to catastrophic organ failure.^[28] Trisomy 21, known as Down syndrome, is the most prevalent autosomal trisomy, occurring in approximately 1 in 833 live births based on 2022 data from England and Wales.^[29] Its incidence rises sharply with maternal age, from about 1 in 1,500 at age 25 to 1 in 100 at age 40.^[30] Approximately 95% of cases involve full trisomy 21, with the remainder mosaic or translocation variants; affected individuals exhibit intellectual disability, characteristic facial features, and increased risk of congenital heart defects (present in 40–50%).^[13] Median survival exceeds 50 years with medical intervention, though comorbidities like Alzheimer's disease emerge earlier.^[13] Trisomy 18, or Edwards syndrome, has a live birth prevalence of about 1 in 11,111 (0.9 per 10,000 births) in recent UK statistics.^[29] Like trisomy 21, risk correlates with advanced maternal age, but overall incidence is roughly 1/6,000–8,000 live births globally.^[31] Over 90% are full trisomies, featuring intrauterine growth restriction, clenched fists with overlapping fingers, rocker-bottom feet, and multiple organ anomalies; 94% involve complete extra chromosome 18 across cells.^[14] Mortality is high, with 50–60% dying within the first week and fewer than 10% surviving past one year, primarily due to cardiac and respiratory failure.^[27]^[32] Trisomy 13, termed Patau syndrome, occurs in 1 in 10,000–16,000 live births, the third most common after trisomies 21 and 18.^[2] Maternal age is a key risk factor, with prevalence increasing from 0.43 to 0.54 per 10,000 births in population studies.^[27] Phenotypes include holoprosencephaly, polydactyly, cleft lip/palate, and microphthalmia; full trisomy predominates, leading to 48% mortality in the first week and median survival under three days.^[27]^[33] Rare mosaic forms confer slightly better outcomes, but overall one-year survival is below 10%.^[27] Other autosomal trisomies, such as those of chromosome 8, 9, or 22, manifest almost exclusively as mosaics or partial forms in survivors, with full versions causing near-universal perinatal lethality; for instance, trisomy 9 full cases yield live births in under 0.1% of conceptions, surviving minutes to months.^[34]^[35] Prenatal loss rates exceed 90% for non-13/18/21 trisomies, underscoring the intolerance of human development to dosage imbalances beyond these chromosomes.^[11]

Sex Chromosome Trisomies

Sex chromosome trisomies encompass conditions featuring an extra X or Y chromosome, yielding a karyotype of 47 chromosomes in affected individuals. The principal variants are 47,XXY (Klinefelter syndrome, affecting males), 47,XXX (triple X syndrome, affecting females), and 47,XYY (affecting males). These arise primarily from nondisjunction during meiosis, with the extra chromosome originating maternally in approximately 50-60% of cases for XXY and XXX, and often paternally for XYY due to Y chromosome nondisjunction.^[36]^[37] Unlike autosomal trisomies, sex chromosome trisomies exhibit high viability, with survival to term exceeding 90% and phenotypes moderated by mechanisms such as X-chromosome inactivation, which silences excess X-linked genes in XXY and XXX cells.^[38] Klinefelter syndrome (47,XXY) has a prevalence of approximately 1 in 500 to 1 in 1000 male newborns, based on newborn screening and cytogenetic surveys.^[36]^[38] Triple X syndrome (47,XXX) occurs in about 1 in 1000 female newborns, with estimates derived from similar population-based karyotyping data.^[39] 47,XYY syndrome manifests in roughly 1 in 1000 male newborns, confirmed through large-scale chromosomal analyses of unselected populations.^[40]^[41] Collectively, these trisomies account for the majority of viable sex chromosome aneuploidies, with an overall incidence of about 1 in 500 live births when including both trisomies and related variants, though many cases remain undiagnosed until adulthood due to subtle or absent clinical features at birth.^[42] Phenotypic expression varies by type but is generally less severe than in autosomal trisomies. In 47,XXY, common traits include tall stature, hypogonadism, and infertility, with increased risks for learning disabilities and endocrine issues emerging post-puberty; however, intelligence is typically within normal range, and many individuals lead independent lives without intervention.^[36] 47,XXX is associated with taller stature, potential menstrual irregularities, and mild cognitive delays in some cases, but most affected females exhibit no significant physical anomalies and normal fertility.^[39] For 47,XYY, individuals often display increased height and minor behavioral challenges, such as impulsivity, but lack consistent physical malformations and have average IQs comparable to the general population; fertility is usually preserved.^[40] Mosaic forms (e.g., 46,XY/47,XXY) occur in 10-20% of cases across types, potentially attenuating symptoms depending on the proportion of trisomic cells.^[37] Diagnosis rates have risen with prenatal screening, but postnatal detection relies on clinical suspicion or incidental findings, underscoring underascertainment in prevalence estimates.^[43]

Human Clinical Aspects

Viable Forms and Phenotypes

The viable trisomies in humans that permit live birth and postnatal survival, though often with substantial morbidity, are limited to autosomal chromosomes 13, 18, and 21, as well as sex chromosomes X and Y. These conditions arise from meiotic nondisjunction, resulting in gene dosage imbalances that disrupt normal development, with phenotypes reflecting the overexpressed genes on the extra chromosome. Autosomal cases generally confer more severe multisystem involvement due to the lack of dosage compensation mechanisms present in sex chromosomes, leading to higher lethality; however, advances in supportive care have extended survival in select cases.^[44]^[13] Trisomy 21 (Down syndrome) manifests with mild to moderate intellectual disability (IQ typically 50-70), growth retardation, and distinctive dysmorphic features including upslanting palpebral fissures, epicanthal folds, flat nasal bridge, and macroglossia. Common comorbidities include congenital heart defects in up to 50% of cases (e.g., atrioventricular septal defects in 40%, ventricular septal defects in 32%), gastrointestinal anomalies such as duodenal atresia or Hirschsprung disease (2%), hypotonia, increased infection susceptibility, hearing loss (60-80%), vision impairments (e.g., cataracts, refractive errors), thyroid dysfunction, and a 10-20-fold elevated leukemia risk. The condition occurs in 1 in 319 to 1 in 1,000 live births, with incidence rising with maternal age due to nondisjunction in oogenesis; approximately 95% are full trisomy, 4% translocation, and 1% mosaic. Survival has improved markedly, with 1-year rates exceeding 90% overall (96% without heart defects, 78% with), and median life expectancy now around 60 years, attributable to surgical interventions and infection management rather than inherent viability improvements.^[13]^[10]^[45] Trisomy 18 (Edwards syndrome) presents with profound intrauterine and postnatal growth restriction, microcephaly, micrognathia, low-set malformed ears, clenched fists with overlapping digits (index over third, fifth over fourth), rocker-bottom feet, and severe central nervous system anomalies including agenesis of the corpus callosum. Over 90% exhibit congenital heart defects (e.g., ventricular septal defect, patent ductus arteriosus), alongside renal malformations, omphalocele, diaphragmatic hernia, and profound intellectual disability if surviving infancy. Prevalence at live birth is 1 in 3,600 to 1 in 10,000, with a female predominance (3:2 ratio) and 95% full trisomy cases; many pregnancies end in spontaneous loss. Survival is poor, with 50% of live births dying in the first week, 60-75% by one month, and only 5-10% reaching one year, though mosaic variants and females show slightly better outcomes; intensive interventions like cardiac surgery can yield 30-50% one-year survival in selected cases.^[14]^[46] Trisomy 13 (Patau syndrome) features holoprosencephaly (forebrain failure to divide, in ~60%), microphthalmia or anophthalmia, cleft lip/palate, postaxial polydactyly, scalp defects (cutis aplasia), congenital heart disease (80%, e.g., ventricular septal defect), polycystic kidneys, and urogenital anomalies, alongside severe growth delay and profound developmental impairment. Midline facial and brain defects stem from disrupted prechordal mesoderm signaling. Incidence is 1 in 10,000 to 20,000 live births, with >95% antenatal lethality; ~90% of diagnoses occur prenatally in developed settings. Prognosis remains dismal, with ~50% mortality in the first month, 90% by one year, and only 6-12% surviving past infancy; rare long-term survivors (e.g., to adulthood) occur with mosaicism or aggressive care, but most exhibit intractable seizures, apnea, and feeding issues.^[47]^[48] Sex chromosome trisomies are more compatible with viability and often milder phenotypes, owing to X-inactivation and Y-chromosome gene sparsity, resulting in variable expressivity and frequent underdiagnosis. 47,XXY (Klinefelter syndrome) affects ~1 in 500-1,000 males, with tall stature, hypogonadism (small testes, low testosterone), gynecomastia, infertility (azoospermia in 100%), and learning/language delays; motor skill deficits and executive function issues occur in ~50-75%, alongside increased risks for autoimmune disorders, osteoporosis, and metabolic syndrome, though many remain asymptomatic until adulthood evaluation for infertility.^[36] 47,XXX (triple X syndrome) occurs in 1 in 1,000 females, featuring tall stature, subtle facial differences, premature ovarian insufficiency (in ~10-20%), menstrual irregularities, and mild cognitive/learning delays (e.g., speech, reading); seizures or renal anomalies affect ~10%, but most achieve normal fertility and intellect, with phenotypes often undetected without karyotyping.^[49] 47,XYY impacts 1 in 1,000 males, primarily with increased height, minor skeletal anomalies, and potential developmental delays in speech/motor skills or executive function; behavioral challenges like ADHD (up to 62% in some cohorts) and autism spectrum traits are reported, yet IQ is typically average and fertility unaffected, with ~98% undiagnosed due to minimal physical stigmata.^[40]^[50]

Lethal and Mosaic Variants

Full trisomies of autosomes other than chromosomes 13, 18, and 21 are typically lethal during embryonic or fetal development, resulting in spontaneous abortion, often in the first trimester.^[51] Trisomy 16 represents the most common such aneuploidy, accounting for approximately 6% of first-trimester miscarriages and up to 16% of early spontaneous abortions in some analyses.^[52] ^[53] These pregnancies frequently exhibit features such as empty gestational sacs, disorganized embryos, or intrauterine growth restriction (IUGR) prior to loss, with rare live births limited to mosaic forms rather than complete trisomy.^[54] Other lethal full trisomies, including those of chromosomes 2, 8, 9, 22, and most non-13/18/21 cases, similarly disrupt critical gene dosage and embryonic patterning, leading to non-viable outcomes before term.^[15] Mosaic trisomies, where a subset of cells contains the extra chromosome while others are euploid, arise from post-zygotic nondisjunction or anaphase lag and can permit survival beyond what full trisomy allows, though prognosis varies by the proportion and distribution of affected cells.^[55] Clinical manifestations often include IUGR, congenital anomalies (e.g., cardiac defects, craniofacial dysmorphism, limb malformations), developmental delays, and increased mortality risk, with severity correlating to higher mosaicism levels in fetal tissues rather than placental alone.^[56] ^[57] For instance, mosaic trisomy 9 presents with diverse features like growth retardation and organ malformations but milder than complete forms, enabling some long-term survival with supportive care.^[58] Prenatal diagnoses of mosaicism carry uncertain outcomes; true fetal mosaicism elevates risks for physical and neurodevelopmental disabilities, particularly if ultrasound anomalies are present, though low-level or confined placental mosaicism may yield unaffected infants.^[59] ^[60] Postnatal confirmation via multiple tissues is essential, as outcomes range from neonatal lethality to childhood survival with variable impairments.^[61]

Diagnosis and Screening

Diagnostic Techniques

Conventional karyotyping remains the gold standard for diagnosing trisomies, involving the culture of fetal or postnatal cells, followed by metaphase chromosome preparation, G-banding staining, and microscopic examination to identify an extra chromosome in the full complement of 47 instead of 46.^[2] This method detects numerical abnormalities like trisomy 21, 18, or 13 with high accuracy but requires 7-14 days for cell culture and analysis, limiting its use for urgent prenatal decisions.^[62] For faster confirmation of common trisomies, fluorescence in situ hybridization (FISH) targets specific chromosomes using fluorescent probes on interphase or metaphase cells, allowing detection of an extra signal indicative of trisomy within 24-48 hours without culturing.^[2] FISH is particularly applied to samples from chorionic villus sampling (CVS) or amniocentesis for trisomies 13, 18, 21, and sex chromosome aneuploidies, offering over 99% sensitivity for these targets but missing unexpected abnormalities outside the probed regions.30450-1/fulltext) Quantitative fluorescent polymerase chain reaction (QF-PCR) provides rapid molecular enumeration of chromosome copies by amplifying short tandem repeats (STRs), detecting three alleles or peak imbalances signaling trisomy in 24-48 hours, ideal for common aneuploidies with near 100% specificity when maternal cell contamination is absent.^[63] This technique analyzes uncultured samples but cannot visualize structural variants or mosaicism below detection thresholds. Chromosomal microarray analysis (CMA), including array comparative genomic hybridization (aCGH) or single nucleotide polymorphism (SNP) arrays, quantifies DNA copy number variations and surpasses karyotyping in resolving submicroscopic imbalances, though for pure trisomies, it confirms the whole-chromosome gain equivalently while identifying concurrent copy number variants in up to 6% of cases.^[62] Recommended by the American College of Obstetricians and Gynecologists for prenatal diagnosis, CMA requires 3-7 days and complements karyotyping for comprehensive evaluation, especially in cases with ultrasound anomalies.^[64]

Prenatal Detection Methods

Prenatal detection of trisomies distinguishes between non-invasive screening methods, which assess risk without direct fetal sampling, and invasive diagnostic tests that provide definitive results but carry procedural risks. Screening is typically offered to all pregnancies, while diagnostics are recommended for high-risk cases identified by screening or other factors such as advanced maternal age.^[65] Non-invasive prenatal testing (NIPT), utilizing cell-free fetal DNA in maternal blood, screens for common trisomies including 21, 18, and 13 with high accuracy starting from 10 weeks gestation. NIPT demonstrates sensitivity of approximately 99% for trisomy 21, 98% for trisomy 18, and over 90% for trisomy 13, with specificities exceeding 99% across these conditions, outperforming traditional serum-based screening in reducing false positives.^[66]^[67] However, NIPT remains a screening tool requiring confirmatory invasive testing for positive results, as false positives can arise from maternal or placental factors.^[68] First-trimester combined screening integrates nuchal translucency ultrasound measurement with maternal serum markers like pregnancy-associated plasma protein-A (PAPP-A) and free beta-human chorionic gonadotropin (β-hCG), achieving detection rates of 85-90% for trisomy 21 at a 5% false-positive rate.^[69] Second-trimester quadruple screening evaluates alpha-fetoprotein, hCG, estriol, and inhibin-A, but yields lower detection rates around 80% for trisomy 21. Ultrasound alone detects structural anomalies associated with trisomies, such as increased nuchal fold or cardiac defects, but sensitivity varies by trisomy type and operator expertise.^[70] Chorionic villus sampling (CVS), performed between 10 and 13 weeks, involves aspiration of placental villi for karyotyping or chromosomal microarray analysis to diagnose trisomies directly, with a miscarriage risk of about 0.5-1%.^[71]^[72] Amniocentesis, conducted from 15 weeks onward, extracts amniotic fluid containing fetal cells for similar genetic analysis, offering miscarriage risks of 0.1-0.3% in experienced centers.^[73]^[65] Both invasive methods enable rapid aneuploidy detection via fluorescence in situ hybridization (FISH) within days, with full karyotyping taking 1-2 weeks, and are gold standards for confirming NIPT findings.^[74]

Ethical and Societal Controversies

Selective Termination Practices

Selective termination practices, in the context of trisomy detection, primarily encompass the elective abortion of fetuses diagnosed with trisomic conditions, either in singleton pregnancies or through targeted reduction of affected fetuses in multifetal gestations. In singleton cases, termination decisions follow confirmatory diagnostic tests such as amniocentesis or chorionic villus sampling, with rates varying by jurisdiction and trisomy type; for trisomy 21, these range from approximately 67% in the United States to 93% in the United Kingdom and nearly 100% for trisomies 13 and 18 across multiple studies.^[75]^[76]^[77] In multifetal pregnancies, particularly dichorionic twins discordant for trisomy, selective reduction targets the anomalous fetus to mitigate risks like preterm birth and maternal complications inherent to higher-order multiples, with procedures typically performed between 11 and 14 weeks gestation.^[78]^[79] The standard technique for selective reduction involves ultrasound-guided transabdominal or transvaginal injection of potassium chloride into the affected fetus's cardiac tissue, achieving technical success in 100% of cases in reported series, though overall pregnancy loss rates prior to 24 weeks range from 5.4% to 12.6%, higher with methods like air embolization (41.7%) compared to potassium chloride (8.3%).^[80]^[81] Live birth rates for remaining fetuses exceed 95% in experienced centers, with no significant increase in miscarriage compared to unreduced twins when reducing to twins.^[82]^[83] These outcomes are empirically linked to reduced perinatal morbidity, as multifetal reductions lower preterm delivery risks without elevating congenital anomaly rates in survivors.^[84]^[85] Practices are more prevalent in assisted reproductive technologies due to induced multifetal rates, with selective decisions informed by nuchal translucency screening, non-invasive prenatal testing, or invasive diagnostics revealing discordance.^[86] Termination rates post-diagnosis reflect parental autonomy but contribute to population-level declines in trisomy births; for instance, Iceland reports virtual elimination of Down syndrome live births via such selections.^[87] Critics, including disability rights advocates, contend these practices imply eugenic devaluation of trisomic lives, prioritizing genetic "normality" over intrinsic value, while proponents emphasize evidence-based risk reduction for viable outcomes.^[88]^[78] Empirical data from registries indicate no long-term psychological harm to parents electing reduction, though decisions often weigh prognostic lethality of trisomies 13 and 18 against viable phenotypes in trisomy 21.^[89]^[90]

Broader Implications and Viewpoints

High termination rates following prenatal diagnosis of trisomy 21 have led to significant reductions in live births with Down syndrome in multiple countries, with rates approaching 100% in Iceland and over 95% in Denmark.^[91]^[92] In the United Kingdom, approximately 90% of diagnosed pregnancies are terminated, contributing to a stabilized or declining prevalence despite stable incidence from maternal age trends.^[93] These patterns reflect broader societal shifts toward prenatal screening technologies like noninvasive prenatal testing (NIPT), which increase detection and enable selective termination, potentially resulting in the near-elimination of Down syndrome from certain populations.^[94] Disability rights advocates argue that such practices undermine the intrinsic value of lives with trisomies, equating high termination rates to a form of eugenics that discriminates against disabled individuals by prioritizing neurotypical or non-disabled outcomes.^[95]^[88] Organizations representing people with Down syndrome, such as those advocating for inclusion in policy debates, contend that routine screening devalues their community and fosters societal perceptions of disability as inherently burdensome, potentially reducing public support for accommodations and research into supportive interventions.^[96]^[97] This perspective emphasizes empirical quality-of-life data showing many individuals with trisomy 21 report high life satisfaction, challenging assumptions embedded in counseling that frame the condition as predominantly negative.^[98] In contrast, proponents of parental autonomy, often aligned with reproductive rights frameworks, maintain that selective termination for trisomy respects individual choice amid evidence of associated health challenges, including intellectual disability, congenital heart defects, and reduced life expectancy averaging 60 years with modern care.^[99]^[100] They argue that bans on abortions motivated by trisomy diagnoses, as enacted in some U.S. states since 2017, infringe on women's rights without addressing underlying resource strains on families and healthcare systems.^[101] Bioethicists in this camp highlight causal realities of nondisjunction leading to multisystem impairments, positing that informed decisions mitigate suffering rather than endorse discrimination.^[90] Even within affected families, viewpoints diverge, with some parents of children with Down syndrome supporting access to termination to avoid perceived hardships, while others view it as a rejection of their child's worth, illustrating internal community tensions.^[101] Critics from disability perspectives warn of a slippery slope where expanded screening for milder aneuploidies, like sex chromosome trisomies, could erode genetic diversity and normalize ability-based selection, though empirical data on long-term population effects remain limited.^[102] These debates underscore tensions between empirical risks of trisomy—such as 80-90% lethality for trisomies 13 and 18—and philosophical questions of human dignity, with source credibility varying: peer-reviewed studies provide termination data, while advocacy positions from disability groups offer lived-experience insights often underrepresented in mainstream medical literature.^[103]^[104]

Management and Prognosis

Supportive Interventions

Supportive interventions for trisomy disorders emphasize multidisciplinary management to address associated congenital anomalies, developmental delays, and comorbidities, rather than correcting the underlying genetic imbalance. These approaches prioritize symptom relief, quality of life enhancement, and family support, tailored to the specific trisomy type and individual prognosis. For viable forms like trisomy 21, care involves proactive health surveillance and therapeutic supports; for lethal variants such as trisomies 13 and 18, interventions often focus on palliative measures, though parental preferences may influence the intensity of care offered.^[105]^[14] In trisomy 21 (Down syndrome), health supervision guidelines recommend routine evaluations starting from birth, including echocardiography for congenital heart defects (affecting approximately 40-50% of cases), thyroid function screening at birth and annually thereafter, and assessments for hearing loss (prevalent in 60-80% of individuals) and vision impairments like cataracts or refractive errors.^[106] Early intervention programs, mandated under U.S. law such as the Individuals with Disabilities Education Act, provide physical, occupational, and speech therapies from infancy to mitigate motor delays, hypotonia, and communication challenges, with evidence showing improved developmental outcomes when initiated before age 3.^[107] Surgical corrections for issues like atrioventricular septal defects or gastrointestinal malformations (e.g., duodenal atresia in 5-12% of cases) are common, alongside leukemia surveillance due to a 10-20-fold increased risk of acute lymphoblastic leukemia.^[108] Multidisciplinary teams, including pediatricians, cardiologists, endocrinologists, and therapists, coordinate care to manage obesity risks through diet and exercise, as untreated excess weight contributes to comorbidities like sleep apnea and diabetes in adulthood.^[109] Life expectancy has risen to around 60 years with these interventions, though intellectual disability (IQ typically 50-70) and early-onset Alzheimer's dementia remain inherent.^[106] For trisomies 13 and 18, which carry high infant mortality (over 90% succumb within the first year), supportive care centers on palliative strategies such as nutritional support via gastrostomy tubes for feeding difficulties, respiratory assistance for apnea or central hypoventilation, and pain management for conditions like seizures or contractures.^[110]^[14] While historically comfort-focused, recent guidelines endorse a "trial of therapy" period in the neonatal intensive care unit to evaluate responsiveness to interventions like prostaglandin for duct-dependent heart lesions or mechanical ventilation, allowing informed parental decisions on pursuing aggressive measures such as cardiac surgery, which can extend survival beyond 1 year in select cases (e.g., 5-10% for full trisomy 18) but often with profound neurological impairment.^[105] Hospice and home-based palliative programs integrate multidisciplinary input from neonatologists, palliative specialists, and social workers to address family emotional needs, with studies indicating that such holistic support improves caregiver satisfaction despite limited survival gains.^[111] Surgical interventions are weighed against evidence of high perioperative mortality (up to 50% for complex repairs) and ongoing dependence on technology.^[112]

Emerging Therapeutic Approaches

Research into emerging therapeutic approaches for trisomies, particularly trisomy 21 (Down syndrome), has focused on strategies to mitigate gene dosage imbalances caused by the extra chromosome, though most remain preclinical. Gene editing technologies, such as CRISPR/Cas9, have demonstrated potential in vitro to correct aneuploidy by inducing allele-specific chromosome cleavage, selectively eliminating the supernumerary chromosome in trisomy 21 cells while preserving euploid karyotypes in edited populations.^[113] Similar allele-specific elimination has been achieved in trisomy 18 (Edwards syndrome) fibroblasts using synthetic mRNAs encoding ZSCAN4, restoring disomic states confirmed by whole-exome sequencing.^[114] These chromosomal correction methods aim at root-cause intervention but face challenges including off-target effects, delivery efficiency, and ethical hurdles for germline or early embryonic application, with no human clinical trials reported as of 2025.^[115] Antisense oligonucleotides (ASOs) represent another targeted approach, reducing expression of overexpressed genes on the extra chromosome to normalize dosage without altering karyotype. For instance, ASOs against the APP gene on chromosome 21 have reduced amyloid-β aggregation and neurodegeneration in Down syndrome models, addressing early-onset Alzheimer's disease prevalent in trisomy 21.^[116] ASOs targeting DYRK1A, another dosage-sensitive gene, show promise in preclinical models for improving cognitive deficits by downregulating transcript levels selectively.^[117] Clinical advancement includes the ION269 ASO in phase 1b trials (HERO study) for Alzheimer's in Down syndrome, administered intrathecally to modulate amyloid pathology.^[118] Limitations include potential incomplete suppression and tissue-specific delivery issues, particularly for brain-targeted therapies. Pharmacological interventions targeting downstream pathways, such as inflammation, oxidative stress, and neurogenesis, are under investigation via multi-omics studies and mouse models of trisomy 21. The ICOD project advances small-molecule therapies for cognitive impairment, focusing on synaptic plasticity enhancers.^[119] Ex vivo cellular therapies, including editing patient-derived induced pluripotent stem cells to correct trisomy before differentiation into affected tissues, offer proof-of-concept for personalized medicine but require scalable manufacturing.^[120] Overall, while these approaches hold theoretical promise for viable trisomies like 21, lethal forms such as trisomy 18 lack advanced trials, emphasizing supportive care; translation to humans demands rigorous safety validation amid variable mosaicism and ethical considerations.^[121]

Occurrence in Other Species

Examples in Animals

Trisomies in non-human animals are rare and typically result in embryonic lethality or severe congenital defects, with survival to birth far less common than in human trisomy 21 due to stricter dosage compensation mechanisms and differing karyotypes across species.^[122] Documented cases often involve cytogenetic analysis of domestic or captive animals presenting with abnormalities such as growth retardation, organ malformations, and infertility.^[123] In equines, autosomal trisomies have been identified through karyotyping. For instance, two cases of non-mosaic trisomy 27 were detected in horses, one in a foal with dysmorphic features including a shortened neck and limb deformities, confirmed via G-banding and FISH techniques in 2025.^[124] Similarly, a non-mosaic trisomy 26 was reported in a horse in 2022, where equine chromosome 26 exhibits synteny with regions of human chromosome 21, leading to phenotypes overlapping with Down syndrome such as intellectual impairment analogs and cardiac issues.^[125] Among primates, trisomy 16 occurs sporadically and is linked to multiple anomalies. A pigtailed macaque (Macaca nemestrina) born in 1998 exhibited full trisomy 16, manifesting in low birth weight, craniofacial dysmorphology, cardiac septal defects, and early postnatal death at 11 days, as verified by metaphase chromosome analysis; this marks one of few viable primate cases beyond embryonic stages.^[126] In murine models engineered to approximate human trisomy 21, partial trisomies of chromosome 16 segments orthologous to human chromosome 21q are prevalent for research, though natural full trisomies are embryonic lethal. The Ts65Dn mouse strain, established in the 1990s, harbors ~50% duplication of the Down syndrome critical region, resulting in observable traits like hippocampal atrophy, impaired learning in Morris water maze tests, and hyperactivity, providing causal insights into gene dosage effects without exact natural replication.^[122]^[127] Sex chromosome trisomies, such as XXY (Klinefelter syndrome analog), appear more frequently in felines and can be diagnosed in up to 11% of tortoiseshell-patterned male cats via cytogenetics, often correlating with sterility and subtle somatic anomalies, though not strictly autosomal.^[123] In canines and felines, autosomal trisomies beyond sex chromosomes remain undocumented in natural populations due to 39 and 19 chromosome pairs respectively, precluding direct human trisomy 21 homologs, with aneuploidies instead manifesting as sporadic developmental disorders.^[123]

Examples in Plants and Microorganisms

In plants, trisomy is relatively more viable than in animals, allowing for the production and study of primary trisomics—individuals with an extra copy of one chromosome—in various species for cytogenetic mapping and gene localization. For instance, in Datura stramonium (jimson weed), which has 12 chromosome pairs, primary trisomics for specific chromosomes display characteristic morphological defects, such as altered leaf shape or flower abnormalities, enabling researchers to associate phenotypes with particular chromosomes.^[128] Similarly, in tomato (Solanum lycopersicum), sets of primary and secondary trisomics have been developed and identified through morphological markers and meiotic behavior, facilitating genome analysis and linkage studies.^[129] In diploid Agropyron cristatum (crested wheatgrass), primary trisomics were generated via crosses involving unreduced gametes, with identification confirmed by fluorescence in situ hybridization (FISH), revealing transmission rates of 20-40% through female gametes but near-zero through pollen.^[130] In Arabidopsis thaliana, trisomic plants for individual chromosomes, such as trisomy 1, exhibit severe growth reductions, sterility, and gene expression perturbations, with effects varying by chromosome size and gene content; for example, trisomy for chromosome 1 causes more pronounced viability loss than double trisomies involving smaller chromosomes.^[131] Rice (Oryza sativa) trisomics, numbering 12 types corresponding to its haploid chromosome set, have been used to test linkage group independence, with trisomic analysis showing distorted segregation ratios due to preferential pairing.^[132] In oilseed rape (Brassica napus), a trisomy for chromosome C2 was identified through cytological and transcriptomic methods, demonstrating genome-wide gene dosage imbalances that affect oil content and stress responses.^[133] Soybean (Glycine max) primary trisomics, originating from anther culture or interspecific hybrids, support cytogenetic mapping by associating markers with specific chromosomes via trisomic inheritance patterns.^[134] Among microorganisms, trisomy and broader aneuploidy are studied primarily in unicellular eukaryotes like yeast, where cells can propagate with extra chromosomes despite fitness costs. In Saccharomyces cerevisiae, aneuploid strains including trisomies arise spontaneously at rates elevated in mutator backgrounds, leading to phenotypes such as slowed growth and proteostasis defects, though wild isolates show varying tolerance linked to genetic modifiers.^[135]^[136] For example, disomic (extra chromosome) sake brewery strains of S. cerevisiae exhibit improved fermentation efficiency and flavor profiles, with specific trisomies enhancing ethanol tolerance and aroma compound production under industrial conditions.^[137] Aneuploid S. cerevisiae cells maintain viability across generations but display unique transcriptional profiles, including upregulation of stress response genes, underscoring aneuploidy's role as both a segregational error and potential adaptation mechanism in microbial evolution.^[138]^[139] In contrast, prokaryotes like bacteria rarely exhibit true trisomy due to their single circular chromosomes and lack of linear eukaryotic structures, though experimental plasmid-based duplications mimic dosage effects.

Evolutionary and Biological Context

Natural Occurrence and Selection Pressures

Trisomies arise naturally through errors in chromosome segregation, primarily nondisjunction during meiosis, where homologous chromosomes or sister chromatids fail to separate properly, resulting in gametes with an extra chromosome.^[3] In humans, approximately 90% of trisomy 21 cases originate from maternal meiotic nondisjunction, often in meiosis I, with the remainder involving meiosis II or rare paternal errors.^[19] This process is exacerbated by advanced maternal age, as oocyte aging impairs spindle assembly and cohesion, elevating nondisjunction rates from about 2% in women under 25 to over 40% in those over 40.^[140] While nondisjunction can theoretically affect any chromosome, only a subset—such as autosomes 13, 18, and 21, or sex chromosomes—yield viable pregnancies, as others typically cause early embryonic arrest due to gene dosage imbalances disrupting development.^[11] At birth, trisomy incidence remains low owing to substantial prenatal selection, with most affected conceptions ending in spontaneous abortion. Trisomy 21 manifests in roughly 1 in 700 live births overall, though precise population rates vary; trisomy 13 occurs in 0.43–0.54 per 10,000 births, and trisomy 18 in 0.96–1.12 per 10,000.^[27] These figures reflect de novo origins in nearly all full trisomy cases, as affected individuals exhibit meiotic instability that precludes transmission of the extra chromosome to offspring in viable forms.^[141] Translocation variants, comprising about 4% of trisomy 21, are 75% de novo and 25% inherited from balanced carriers, but autosomal trisomies as a class rarely propagate intergenerationally.^[141] Selection pressures act stringently against trisomies, enforcing a mutation-selection balance that maintains low population frequencies despite recurrent nondisjunction. Embryonic and fetal lethality eliminates the majority—over 70–80% for trisomies 13 and 18—before term, driven by proteotoxic stress and disrupted cellular homeostasis from excess gene products.^[11] Among live births, survivors face elevated mortality (e.g., 5–10% of trisomy 18 cases past one year) and profound fitness costs, including intellectual disability, congenital anomalies, and infertility or subfertility, yielding near-zero reproductive success in population terms.^[46] This purifying selection, rooted in causal gene dosage effects rather than adaptive benefits, counters the baseline error rate of meiosis, preventing accumulation; evolutionary models indicate no net advantage to trisomy persistence beyond transient cellular responses in non-developmental contexts, which do not apply to whole-organism viability in mammals.^[142]

Population-Level Patterns

The most common autosomal trisomies—trisomy 21 (Down syndrome), trisomy 18 (Edwards syndrome), and trisomy 13 (Patau syndrome)—exhibit distinct population-level prevalence rates, with trisomy 21 occurring at a birth incidence of approximately 1 in 700 to 1 in 1,000 live births globally, trisomy 18 at 1 in 5,000 to 1 in 6,000, and trisomy 13 at 1 in 10,000 to 1 in 16,000.^[143]^[144] These rates reflect live births and are influenced by high fetal lethality, particularly for trisomies 13 and 18, where over 90% of affected pregnancies end in spontaneous abortion or stillbirth.^[145] Total prenatal detection rates are higher, with trisomy 21 fetal prevalence around 1 in 300 to 1 in 400 pregnancies, underscoring substantial natural selection against aneuploidy at early developmental stages.^[146] Geographic variations exist but are largely attributable to differences in maternal age distributions and prenatal screening/termination practices rather than inherent genetic factors.^[143] Advanced maternal age is the primary risk factor across populations, with nondisjunction errors in maternal meiosis I accounting for 90% of trisomy 21 cases and showing exponential increases in incidence: approximately 1 in 1,500 at age 20–24, rising to 1 in 350 at age 35, and 1 in 100 at age 40.^[147]^[148] Similar age-dependent patterns hold for trisomies 18 and 13, though their baseline rates are lower and associated with even higher miscarriage risks.^[149] Paternal age contributes minimally, with studies indicating only a modest effect beyond 40 years.^[26] Ethnic differences in live birth prevalence are modest and primarily mediated by variations in average maternal age at conception; for instance, non-Hispanic whites exhibit higher trisomy 21 rates at advanced ages compared to Black or Hispanic groups, potentially due to differences in age-specific nondisjunction risks or reproductive patterns.^[150] Sex ratios at birth deviate from the typical 1.05 male:female, with trisomy 21 showing a slight female predominance (approximately 1.2–1.4 females per male), while trisomies 18 and 13 display stronger female biases (up to 3:1), linked to greater male fetal lethality in aneuploid pregnancies.^[143] Population trends over time reveal stable underlying fetal incidences but declining live birth rates in regions with widespread prenatal diagnosis and selective termination, such as a reported drop in trisomy 21 live births despite rising maternal ages in some cohorts.^[143] These patterns align with evolutionary pressures, as trisomies confer near-zero reproductive fitness, limiting their persistence to de novo events rather than transmission.^[149]

References

[1]
Trisomies Reorganize Human 3D Genome - PMC - PubMed Central
Nov 7, 2023 · Trisomy is the presence of one extra copy of an entire chromosome or its part in a cell nucleus. In humans, autosomal trisomies are ...
[2]
Genetics, Chromosome Abnormalities - StatPearls - NCBI Bookshelf
Apr 24, 2023 · For example, trisomy (three copies of a specific homologous chromosome or 2N + 1) is the most frequent constitutional chromosomal abnormality ...
[3]
Genetics, Nondisjunction - StatPearls - NCBI Bookshelf - NIH
Mitotic nondisjunction can occur due to the inactivation of either topoisomerase II, condensin, or separase.
[4]
Down Syndrome (Trisomy 21) - Pediatrics - Merck Manuals
In approximately 95% of cases, Down syndrome is caused by nondisjunction resulting in an extra chromosome 21 (trisomy 21), which is typically maternally derived ...
[5]
Multipoint Genetic Mapping with Trisomy Data - PMC
Trisomy is the most commonly identified chromosome abnormality in humans, occurring in 0.3% of live births, 4% of stillbirths, and as many as 25% of spontaneous ...
[6]
Types of Trisomy Disorders - Cleveland Clinic
Trisomy is a genetic condition where a person is born with an extra chromosome. The most common type of trisomy is Down syndrome.
[7]
Trisomy 21 (Down Syndrome) - Children's Hospital of Philadelphia
Trisomy 21 is the most common of the three, occurring in 1 out of every 691 births. The disorder was first identified in 1866 by John Langdon Down, a British ...
[8]
Trisomy 18 and 13 | Boston Children's Hospital
For example, trisomy 21, or Down syndrome, occurs when a baby has three #21 chromosomes. Other examples are trisomy 18 and trisomy 13, fatal genetic birth ...
[9]
What causes Down syndrome? | NICHD
Feb 16, 2024 · Down syndrome is caused by a random error in cell division that results in the presence of an extra copy of chromosome 21.
[10]
Down Syndrome | Birth Defects - CDC
Dec 26, 2024 · With Trisomy 21, each cell in the body has three separate copies of chromosome 21. About 95% of people with Down syndrome have Trisomy 21.Living with Down Syndrome · Screening for Birth Defects · Diagnosing Birth Defects<|separator|>
[11]
Consequences of chromosome gain: A new view on trisomy ... - NIH
A notable category of genetic disorders is caused by the presence of an extra chromosome. The superfluous genetic material disrupts normal development, causing ...
[12]
Definition of trisomy - NCI Dictionary of Genetics Terms
The presence of an extra chromosome in some or all of the body's cells. This results in a total of three copies of that chromosome instead of the normal two ...
[13]
Down Syndrome - StatPearls - NCBI Bookshelf - NIH
Aug 8, 2023 · Down syndrome (trisomy 21) is a genetic disorder caused by the presence of all or a portion of a third chromosome 21.
[14]
Edwards Syndrome - StatPearls - NCBI Bookshelf - NIH
Feb 15, 2025 · Trisomy 18 is an autosomal chromosomal aneuploidy caused by an extra chromosome 18, leading to various congenital malformations, and is the ...
[15]
Trisomy - an overview | ScienceDirect Topics
Trisomy. Trisomy is the presence of an extra chromosome. This can arise as a result of non-disjunction, when homologous chromosomes fail to separate at ...
[16]
Nondisjunction - an overview | ScienceDirect Topics
Mechanisms Leading to Aneuploidy Nondisjunction is the failure of chromosomes to separate (disjoin) at anaphase during meiosis I (paired homologs), meiosis II ...
[17]
Nondisjunction in trisomy 21: origin and mechanisms - PubMed
In this review we summarize the knowledge about the origin and mechanisms of nondisjunction in human trisomy 21 that has accumulated during the last decade.
[18]
Molecular Analysis of Nondisjunction in Down Syndrome Patients ...
The majority of numerical chromosomal aberrations, such as Down syndrome, result from a nondisjunction error in meiosis.
[19]
Population monitoring of trisomy 21: problems and approaches
May 14, 2023 · About 90% of trisomy 21 cases are due to maternal meiotic nondisjunction, whereby about 70% originate during the first meiotic division [M I] ...
[20]
New Insights into Human Nondisjunction of Chromosome 21 in ...
In this report, we stratified maternal cases of trisomy 21 by the type of nondisjunction error (meiosis I or meiosis II) and by maternal age (ages <29, 29–34 ...
[21]
Down Syndrome: Parental Origin, Recombination, and Maternal Age
The majority of full trisomy 21 is caused by chromosomal nondisjunction occurring during maternal meiotic division (∼90%). Errors occur more frequently in the ...<|separator|>
[22]
Maternal age and risk for trisomy 21 assessed by the origin of ...
We examined the association between maternal age and chromosome 21 nondisjunction by origin of the meiotic error. We analyzed data from two population-based
[23]
Nondisjunction in trisomy 21: Origin and mechanisms
Jan 30, 2001 · The condition is usually the result of malsegregation (nondisjunction) of chromosome 21 in meiosis in either oogenesis or spermatogenesis. The ...
[24]
Etiology of Down Syndrome: Evidence for Consistent ... - NIH
Down syndrome caused by meiotic nondisjunction of chromosome 21 in humans, is well known to be associated with advanced maternal age.
[25]
Nondisjunction in Trisomy 21: Origin and Mechanisms
Aug 29, 2023 · The Trisomy 21 can occur due to Robertsonian translocation, Mosaicisms or duplication of critical region of chromosome 21. The trisomy 21 is the ...<|separator|>
[26]
Maternal age and risk for trisomy 21 assessed by the origin of ... - NIH
Similarly, mothers of infants with trisomy 21 due to MMII nondisjunction were five times more likely to be 35–39 years old than 20–24 years old at the birth of ...
[27]
Trisomy 13 and 18—Prevalence and mortality—A multi-registry ...
Trisomy 18 (T18) and trisomy 13 (T13) are the second and third most common autosomal trisomies in live births (LB) after trisomy 21. Previous population ...<|separator|>
[28]
Autosomal Trisomies - an overview | ScienceDirect Topics
Most are lethal before 16 days gestation, very few survive to birth and only trisomy 19 mice have consistently been seen to survive beyond birth (see Table 1 ...
[29]
Prevalence of babies with Down's syndrome, Edwards ... - NHS Digital
Oct 17, 2025 · Live birth prevalence per 10,000 live births in 2022 was 12.0 (95% CI 11.1-12.9) - or one in 833 live births - for Down's syndrome, 0.9 (95% CI ...Missing: viable autosomal
[30]
Review of epidemiological factors (other than maternal age) that ...
The birth prevalence of each common autosomal trisomy (21, 18 and 13) increases with advancing maternal age and this is the most important epidemiological risk ...
[31]
The trisomy 18 syndrome - PMC - PubMed Central - NIH
The condition is the second most common autosomal trisomy syndrome after trisomy 21. The live born prevalence is estimated as 1/6,000-1/8,000, but the overall ...
[32]
Edwards Syndrome (Trisomy 18) - Cleveland Clinic
The survival rate varies for babies born with Edwards syndrome (trisomy 18):. Between 60% and 75% survive to their first week. Between 20% and 40% survive to ...Missing: autosomal | Show results with:autosomal
[33]
Patau Syndrome: Practice Essentials, Pathophysiology, Epidemiology
Oct 13, 2023 · Patau syndrome, also called trisomy 13, is the least common and most severe of the viable autosomal trisomies. Median survival is fewer than 3 days.
[34]
Autosomal Trisomies - an overview | ScienceDirect Topics
Trisomy 13, also known as Patau syndrome, occurs in 0.5 : 10,000–2 : 10,000 births, while the incidence of trisomy 18, or Edwards syndrome, is 2 : 10,000 live ...
[35]
How Long Can You Live With Trisomy 9? - MedicineNet
Only about 0.1% of trisomy 9 pregnancies result in a live birth with survival periods ranging from minutes to 9 months.
[36]
Klinefelter Syndrome - StatPearls - NCBI Bookshelf
May 5, 2025 · The estimated prevalence is between 1 in 500 and 1 in 1000 males. [9] Diagnosis often occurs in adulthood, as many cases remain unidentified ...
[37]
Prevalence and disease risks for male and female sex chromosome ...
Feb 2, 2025 · Sex chromosome trisomies (SCT), characterized by the presence of an additional copy of chromosome X (47,XXY and 47,XXX) or chromosome Y (47,XYY) ...
[38]
Klinefelter syndrome and other sex chromosomal aneuploidies - PMC
XXY aneuploidy is the most common disorder of sex chromosomes in humans, with prevalence of one in 500 males. Other sex chromosomal aneuploidies have also ...
[39]
Medical Findings in Infants Prenatally Identified With Sex ...
Sep 26, 2025 · Sex chromosome trisomies (SCT) occur in approximately 1:500 births and include XXY (Klinefelter syndrome) and XYY syndrome in boys, and XXX ( ...
[40]
Jacobs Syndrome - StatPearls - NCBI Bookshelf - NIH
Jacobs syndrome, also known as 47,XYY syndrome, is a rare genetic condition that occurs in about 1 out of 1000 male children; this condition belongs to a ...
[41]
Morbidity in 47,XYY syndrome: a nationwide epidemiological study ...
Pooling data from a number of newborn chromosome surveys performed decades ago, the 47,XYY syndrome has been estimated to affect approximately 1 per 1000 male ...
[42]
Current survey of early childhood intervention services in infants and ...
May 25, 2020 · Sex chromosome aneuploidies (SCAs) are the most commonly occurring aneuploidies in children with a collective prevalence rate of 1 in 500 live ...
[43]
Prevalence, Morbidity, and Mortality of Men With Sex Chromosome ...
Mar 29, 2024 · Approximately 1 in 400 males have an extra X or Y chromosome, resulting in approximately 5000 males born in the US annually with 47,XXY ( ...
[44]
Trisomy 13, 18, 21, Triploidy and Turner syndrome: the 5T's. Look at ...
In the prenatal period 5 numerical chromosomal malformations are frequently observed, referred here as the 5 T's: trisomy 13, trisomy 18, trisomy 21, triploidy ...
[45]
Trends in Survival Among Children With Down Syndrome in 10 ...
The overall 1-month and 1-, 5-, and 20-year survival probabilities were 98%, 93%, 91%, and 88%, respectively. Over the study period, neonatal survival did not ...Missing: phenotype | Show results with:phenotype
[46]
Trisomy 18 - Genetics - MedlinePlus
Feb 16, 2021 · Trisomy 18, also called Edwards syndrome, is a chromosomal condition associated with abnormalities in many parts of the body.
[47]
Trisomy 13 - StatPearls - NCBI Bookshelf
Aug 13, 2023 · Trisomy 13 is a chromosomal aneuploidy originally described by Patau et al. in 1960.[1] The occurrence of trisomy 13 is 1 in 10000 to 20000 ...Missing: types | Show results with:types<|separator|>
[48]
Trisomy 13 - Genetics - MedlinePlus
Sep 9, 2021 · Trisomy 13 is a chromosomal condition associated with severe intellectual disability and physical abnormalities.
[49]
Triple X syndrome: a review of the literature - PMC - NIH
Jul 1, 2009 · The incidence is 1 of 1000 females. At birth, 47,XXX girls have a lower mean birth weight and a smaller head circumference. Triple X diagnosis ...
[50]
47,XYY syndrome: MedlinePlus Genetics
Mar 2, 2022 · 47,XYY syndrome is associated with an increased risk of learning disabilities and delayed development of speech and language skills. Affected ...Missing: reliable | Show results with:reliable
[51]
https://www.nature.com/scitable/topicpage/chromosomal-abnormalities-aneuploidies-290
[52]
Identification of differentially methylated genes in first-trimester ...
Jan 21, 2022 · Trisomy of chromosome 16 is the most common aneuploidy in miscarriages of the first trimester of pregnancy, and it accounts for approximately 6% ...
[53]
Trisomy 16 - an overview | ScienceDirect Topics
In mosaic trisomy 16, however, a larger proportion of female fetuses exist. Trisomy 16 accounts for 16% of first-trimester spontaneous abortions.
[54]
Prenatally Diagnosed Rare Trisomy 16 Mosaicism in Human ... - NIH
Trisomy 16 accounts for 1-2% or more of all first trimester miscarriages (Neiswanger et al., 2006), and the abortuses show empty sacs, disorganized embryos, or ...
[55]
Mosaicism for Autosomal Trisomies: A Comprehensive Analysis of ...
Jun 13, 2024 · Mosaic Trisomy Profile and Clinical Outcomes in Prenatal Diagnoses. Comparing Mosaic Trisomy Profile in Prenatal and Postnatal Diagnoses.
[56]
Occurrence of mosaic trisomy 22 and pericentric inversion of ...
Nov 13, 2023 · ... extra chromosome 22, while others have the ... Mosaic trisomy 22: a case presentation and literature review of trisomy 22 phenotypes.
[57]
Mosaic Trisomy 9 - Symptoms, Causes, Treatment | NORD
May 17, 2023 · Mosaic trisomy 9 is a rare chromosomal disorder in which the entire 9th chromosome appears three times (trisomy) rather than twice in some cells of the body.
[58]
A Case of Trisomy 9 Mosaicism Confirmed by Microarray Test
The clinical features of infants with trisomy 9 mosaicism are diverse, and, less severe than those of complete types. Infants with partial trisomy 9 may survive ...
[59]
The Impact of Chromosomal Mosaicisms on Prenatal Diagnosis and ...
Jul 21, 2024 · The most frequent true positive rate was seen for mosaic sex chromosome aneuploidies (83.33%), followed by 47,XYY (57.14%), 47,XXY (37.50%), 47, ...
[60]
Clinical management of mosaic results from preimplantation genetic ...
In the presence of ultrasound anomalies, true fetal mosaicism poses an increased risk for developmental and physical disabilities. However, in the absence of ...
[61]
Case report: Detection of fetal trisomy 9 mosaicism by multiple ...
Mar 9, 2023 · The results confirmed the presence of true fetoplacental mosaicism with levels of trisomy 9 mosaicism from 76% to normal in various tissues.<|separator|>
[62]
Prenatal Diagnosis by Chromosomal Microarray Analysis - PMC
CMA is on par with traditional karyotyping for detection of major chromosomal imbalances such as aneuploidy and unbalanced rearrangements.
[63]
Chromosome microarray analysis combined with karyotype analysis ...
Nov 11, 2023 · Karyotype analysis and fluorescence in situ hybridization (FISH) are commonly used for prenatal diagnosis, however they have many disadvantages ...
[64]
Karyotype versus Microarray Testing for Genetic Abnormalities after ...
Dec 6, 2012 · Microarray analysis is more likely than karyotype analysis to provide a genetic diagnosis, primarily because of its success with nonviable tissue.
[65]
Prenatal Diagnostic Testing for Genetic Disorders - ACOG
Although it is necessary to perform amniocentesis or chorionic villus sampling (CVS) to definitively diagnose most genetic disorders, in some circumstances ...
[66]
Noninvasive prenatal testing: an overview - PMC - NIH
Apr 22, 2025 · The most common fetal aneuploidies include Down syndrome (trisomy 21), Edwards syndrome (trisomy 18), and Patau syndrome (trisomy 13). In ...
[67]
Accuracy of non-invasive prenatal testing using cell-free DNA for ...
NIPT using cell-free fetal DNA has very high sensitivity and specificity for Down syndrome, with slightly lower sensitivity for Edwards and Patau syndrome.<|separator|>
[68]
Non-Invasive Prenatal Testing (NIPT): Reliability, Challenges, and ...
Aug 2, 2023 · NIPT was able to demonstrate a high detection rate for autosomal aneuploidies, which led to the suggestion that NIPT be offered as a screening ...
[69]
Prenatal screening for trisomy 21 (Down syndrome) using first- and ...
Aug 6, 2025 · This technical standard was developed as a guide for laboratories performing prenatal screening for Down syndrome.
[70]
Clinical strategy study on prenatal screening and diagnostic model ...
Sep 27, 2024 · The widely implemented clinical strategy for diagnosis is to conduct ultrasound and serum prenatal screening for pregnant women and then obtain ...
[71]
Chorionic Villus Sampling and Amniocentesis - CDC
Chorionic villus sampling (CVS) and amniocentesis are prenatal diagnostic procedures used to detect certain fetal genetic abnormalities. Both procedures ...
[72]
Chorionic Villus Sampling (CVS): What It Is, Benefits & Risks
Chorionic villus sampling (or CVS) is a prenatal test that diagnoses genetic conditions in a fetus by looking at cell samples from the placenta.
[73]
Amniocentesis - StatPearls - NCBI Bookshelf - NIH
Aug 14, 2023 · Amniocentesis is an invasive technique. It is usually performed to diagnose or exclude fetal aneuploidy or other fetal genetic, biochemical or infectious risks.
[74]
Chorionic Villus Sampling for Rapid Confirmation of High‐Risk NIPT ...
Jun 17, 2025 · Our current study shows that CVS can be offered as a valid alternative to amniocentesis for follow-up diagnostic testing in case of high-risk ...
[75]
a systematic review of termination rates (1995–2011) - Natoli - 2012
Mar 14, 2012 · The weighted mean termination rate for all eight studies was 50%, although this was heavily influenced by the largest study, which found a 38% ...INTRODUCTION · METHODS · RESULTS · DISCUSSION
[76]
The Debate Over Terminating Down Syndrome Pregnancies
Dec 6, 2018 · In Denmark, 98 percent of pregnancies with a Down syndrome diagnosis are terminated. In France, it's 77 percent, and in the United States it's ...
[77]
Outcome after Prenatal Diagnosis of Trisomy 13, 18, and 21 in ...
Aug 12, 2022 · In total, 98 (61.3%) families opted for the termination of pregnancy (TOP). Of the remaining 62 (38.8%) pregnancies, 16 (25.8%) resulted in ...
[78]
Multifetal Pregnancy Reduction - ACOG
In selective reduction, fetuses are chosen based on health status. As with all pregnancies, when a woman with a multifetal pregnancy has ultrasonography or ...
[79]
Selective termination in dichorionic twins discordant for congenital ...
The presenting fetus was terminated in 11 cases (39.3%). Selective termination was followed by the subsequent delivery of a viable infant in 27 out of 28 cases ...
[80]
Efficacy of second-trimester selective termination for fetal ... - PubMed
Selective termination was technically successful in 100% of cases. In 23 of 183 (12.6%) miscarriage occurred before 24 weeks; 2 of 37 (5.4%) occurred when the ...Missing: trisomy | Show results with:trisomy
[81]
Efficacy of second-trimester selective termination for fetal ...
Three cases of selective termination performed in monochorionic pregnancies all resulted in pregnancy loss. Among 183 potentially viable deliveries, 7 occurred ...
[82]
Perinatal outcome and timing of selective fetal reduction in ... - NIH
Jan 16, 2024 · The overall live birth rate and the survival rate were 96.5 and 95.4%, respectively. Although the rate of spontaneous miscarriage was comparable ...
[83]
Selective reduction and termination of multiple pregnancies - PubMed
The evidence suggests that reduction to twins significantly reduces the risk of preterm delivery without an increase in miscarriage rates.
[84]
Perinatal outcome and timing of selective fetal reduction ... - Frontiers
Jan 15, 2024 · Conclusion: Selective reduction performed by experienced hands for a dizygotic abnormal twin is safe and effective. Gestational age at surgery ( ...
[85]
Selective Fetal Reduction in Multiple Pregnancies | Article | GLOWM
Here we discuss the evidence-based risks and benefits of selective fetal reduction in different types of multiple pregnancies, the different techniques used,
[86]
Perinatal outcomes of selective termination in dichorionic twin ...
Oct 21, 2024 · The overall live birth rate was 98.7% (224/227). The live birth rates were 96.1% in Group 1, 97% in Group 2, 94.7% in Group 3 (three fetuses ...
[87]
405: Termination rate and stillbirth in pregnancies affected by fetal ...
A total of 157 women chose to have pregnancy termination, of which 107 (73.3%) were in the AMA group. A total of 92 women continued the pregnancy including 51.5 ...
[88]
Banning Abortion for Down Syndrome: Legal or Ethical Justification?
Aug 26, 2015 · A third objection to abortion to prevent the birth a child with Down syndrome comes from the disability rights movement. Its proponents argue ...
[89]
Selective termination in multiple pregnancy - PubMed
Selective termination appeals principally to those located somewhere in the middle of the abortion issue. The procedure does, however, carry some small risks.
[90]
Down's syndrome screening is unethical: views of today's research ...
Screening was considered ethical by 49% (38 of 77), which decreased to 44% (34 of 77) when a cure within 15 years was suggested. Question block E tested whether ...
[91]
Why Down syndrome in Iceland has almost disappeared - CBS News
Aug 15, 2017 · The law in Iceland permits abortion after 16 weeks if the fetus has a deformity -- and Down syndrome is included in this category.Missing: broader | Show results with:broader<|separator|>
[92]
“This is the child we were given”: A qualitative study of Danish ...
In Denmark, the termination rate is >95% when prenatal screening leads to a DS diagnosis [5]. Since the introduction of the national prenatal screening program ...
[93]
Down's syndrome: 'In all honesty we were offered 15 terminations'
Oct 24, 2020 · Ninety per cent of women whose unborn babies are diagnosed with Down's syndrome choose to have an abortion, which is legal right up until ...
[94]
Down Syndrome Statistics by Country (Top 8) in 2025 - DoctorSolve
Mar 14, 2025 · According to an article published on ABC News, Iceland has the lowest rate of Down Syndrome. Extensive prenatal testing and high rates of ...
[95]
Selective Abortion: Involving People with Down's Syndrome in the ...
Jun 6, 2023 · Amy Redhead discusses the ethical necessity of involving people with Down's Syndrome (DS) in discussions of, and debates around, selective abortion (SA).
[96]
Disability rights critique of prenatal genetic testing - PubMed
Many of its adherents believe that public support for prenatal diagnosis and abortion based on disability contravenes the movement's basic philosophy and goals.Missing: perspectives aneuploidy
[97]
Prenatal Testing and Disability Rights | Request PDF - ResearchGate
Disability rights activists and scholars have critiqued the availability and uses of prenatal genetic testing because of the high selective abortion rates, ...
[98]
Clashes of consensus: on the problem of both justifying abortion of ...
Feb 10, 2017 · Abstract. Although the abortion of fetuses with Down syndrome has become commonplace, infanticide is still widely rejected.
[99]
Genetic Selective Abortion: Still a Matter of Choice
Apr 8, 2020 · Selective abortion can be controversial depending on its target, even amongst those who generally hold a liberal pro-choice stance towards ...
[100]
Why reason-based abortion bans are not a remedy against eugenics
Jan 29, 2023 · Here, he points to the high abortion rates in Europe and the United States for pregnancies in which Down syndrome has been identified.
[101]
Down Syndrome Families Divided Over Abortion Ban - NPR
Dec 13, 2017 · Families affected by the genetic disorder, which causes developmental delays, are conflicted over whether such abortions should be legal.
[102]
New Prenatal Genetic Screens Pose Underappreciated Ethical ...
May 5, 2022 · Many more parents will face wrenching dilemmas about selective abortion, the decision to terminate a pregnancy following a positive prenatal ...<|separator|>
[103]
https://pmc.ncbi.nlm.nih.gov/articles/PMC4948186
[104]
Views on disability and prenatal testing among families with Down ...
Various perspectives are brought to the debate, including foetal rights, disability rights, feminist and medical perspectives, and parental autonomy ...
[105]
Guidance for Caring for Infants and Children With Trisomy 13 and ...
Jul 21, 2025 · Introduction. Historically, trisomy 13 (T13) and trisomy 18 (T18) were viewed as uniformly lethal genetic syndromes.
[106]
Health Supervision for Children and Adolescents With Down ...
Apr 18, 2022 · This clinical report is designed to assist the pediatrician in caring for the child, adolescent, and family in whom a diagnosis of Down syndrome has been ...The Prenatal Visit · Examination · Evaluate For · Anticipatory Guidance From 12...
[107]
Children with Down Syndrome: Health Care Information for Families
Nov 14, 2024 · Your child needs regular doctor visits and a few special tests. Pediatric specialists may also need to be involved. AAP guide for families of ...
[108]
Down Syndrome Treatment & Management - Medscape Reference
Dec 6, 2024 · No special diet is required, unless celiac disease is present. A balanced diet and regular exercise are needed to maintain appropriate weight.
[109]
Health Care Management of Adults with Down Syndrome - AAFP
Sep 15, 2001 · Adults with Down syndrome have the same basic health care needs as typically developed people, including health screening and prevention.
[110]
Trisomy 18 Treatment & Management - Medscape Reference
Sep 9, 2025 · Cardiac management is primarily medical. Most of these children require a diuretic and digoxin for congestive heart failure.Approach Considerations · Medical Care · Surgical Care · Consultations
[111]
Trisomy 13, home health-care and multidisciplinary approach
Oct 4, 2024 · During prenatal care, chromosomal abnormalities associated with Patau's syndrome can be detected through ultrasounds, a non-invasive screening ...
[112]
Trisomy 18 - Symptoms, Causes, Treatment | NORD
Trisomy 18 is a rare chromosomal disorder in which all or a critical region of chromosome 18 appears three times (trisomy) rather than twice in cells of the ...<|separator|>
[113]
Trisomic rescue via allele-specific multiple chromosome cleavage ...
Feb 18, 2025 · This supports the hypothesis that extra-chromosome removal rescues trisomy 21 phenotypes regarding integrated gene signature alteration. Tissue ...
[114]
Correction of Down syndrome and Edwards syndrome aneuploidies ...
These findings were confirmed by whole-exome sequencing. Similar results were obtained for cells with the trisomy 18 of Edwards syndrome.
[115]
CRISPR Snips Away Extra Chromosomes, Offering New Hope for ...
Feb 23, 2025 · The method restores normal gene function but is not yet ready for human trials. Scientists are exploring gene editing as a way to correct ...
[116]
APP antisense oligonucleotides reduce amyloid-β aggregation and ...
Jul 5, 2024 · Individuals with Down syndrome (trisomy of chromosome 21) harbour three copies of the APP gene and invariably develop progressive AD with highly ...
[117]
Down syndrome and DYRK1A overexpression - Frontiers
On the other hand, antisense oligonucleotides (ASOs) offer a more selective therapeutic strategy to downregulate DYRK1A expression at the gene transcript level.Abstract · Introduction · Down syndrome · Antisense oligonucleotides
[118]
First Participant With Down syndrome ... in Landmark HERO Study
ION269 is part of a class of medicines called antisense oligonucleotides. Participants in the HERO study will receive an injection of the investigational ...<|control11|><|separator|>
[119]
News and Research - ICOD Project
A project to develop the first pharmacological therapy for cognitive impairment in Down syndrome - ICOD Project.Missing: emerging | Show results with:emerging<|separator|>
[120]
Chromosomal and cellular therapeutic approaches for Down ...
The emerging chromosomal therapies and gene editing technologies stand as promising approaches to correct trisomy 21 in patient cells or perform ex vivo editing ...
[121]
Charting the future: current and future directions in translational ...
Jul 8, 2025 · Here, we review current progress, resources, knowledge gaps, and bottlenecks for precision medicine approaches to promote brain health across the lifespan.
[122]
Rodent models in Down syndrome research: impact and future ... - NIH
Here, we discuss DS mouse models that contain larger trisomic or duplicated chromosomal segments, thereby mimicking the trisomy observed in humans. Early mouse ...
[123]
Chromosome Abnormalities in Domestic Animals as Causes of ...
Mar 23, 2016 · The largest number of XXY trisomy cases was reported in tortoiseshell male cats, and recently such a case was described [51]. In cattle, more ...
[124]
Two Cases of Chromosome 27 Trisomy in Horses Detected ... - NIH
Jun 22, 2025 · While autosomal monosomy is lethal in most species, trisomy of certain autosomes can result in live births; examples include trisomy 21 in ...
[125]
[PDF] The Second Case of Non-Mosaic Trisomy of Chromosome 26 with ...
Mar 22, 2022 · Because horse chr26 shares genetic similarity with human chr21, which trisomy causes Down syndrome, common features between trisomies of horse ...
[126]
Trisomy 16 in a Pigtailed Macaque (M. nemestrina) With Multiple ...
Jan 1, 2004 · Three cases of trisomy 16 in macaques have been reported previously, including a brief report of the animal presented here (Best et al., 1999; ...
[127]
Peer review in Pleiotropic effects of trisomy and pharmacologic ...
Mar 18, 2024 · Ts65dn mice exhibit structural, functional, molecular, and genetic alterations that are modulated but unrecovered by prenatal chronic ...
[128]
Variations in Datura Due to Changes in Chromosome Number
Two forms with which we ha.vTe recently carried on breeding experiments, the garden flower Portulaca and the jimson weed (Datura Stramnoniumn),.
[129]
Trisomics | TGRC - UC Davis
May 24, 2023 · Khush, G.S. and C.M. Rick. (1969) Tomato secondary trisomics: Origin, identification, morphology and use in cytogenetic analysis of the genome. ...Missing: examples | Show results with:examples
[130]
Production and identification of primary trisomics in diploid ...
A study was conducted to produce and identify a primary trisomic series that will be used to map genes to individual chromosomes. A population of 157 plants ...Missing: research examples
[131]
Phenotypic Consequences of Aneuploidy in Arabidopsis thaliana
For example, plants trisomic for chromosome 1 (Tr.1) were much more severely affected than Chr.1, Chr.3 double trisomics (data not shown). Finally, one ...
[132]
Studies on the trisomics in rice plants (Oryza sativa L.) VI ... - j-stage
The trisomic method is the most positive way to test the independence of linkage groups. In order to use trisomics for linkage studies in rice, several workers ...Missing: research examples
[133]
Identification and Genome-Wide Gene Expression Perturbation of a ...
Sep 7, 2023 · In this study, the trisomy plant was eventually demonstrated to harbour a third copy of chromosome C2, which is not the smallest chromosome in B ...
[134]
Primary Trisomics in Soybean: Origin, Identification, Breeding ...
Nov 1, 2000 · The ultimate aim of this project is to develop by means of primary trisomics a universal cytogenetic map of soybean by associating existing classical and ...Missing: examples | Show results with:examples
[135]
Chromosome rearrangements and aneuploidy in yeast strains ... - NIH
These yeast strains had very high frequencies of aneuploidy (both trisomy and monosomy) in addition to elevated rates of chromosome rearrangements.
[136]
The genetic basis of aneuploidy tolerance in wild yeast - eLife
Jan 7, 2020 · Many of the yeast phenotypes previously reported as signatures of aneuploidy, including proteostasis defects, metabolic defects, cell-cycle ...
[137]
Chromosomal Aneuploidy Improves the Brewing Characteristics of ...
Dec 1, 2017 · Here we report that chromosomal aneuploidy in sake brewery yeast (Saccharomyces cerevisiae) leads to the development of favorable brewing ...<|separator|>
[138]
Aneuploidy confers a unique transcriptional and phenotypic profile ...
Apr 6, 2025 · Yeast species have served as an excellent model for investigating aneuploidy because of their ability to propagate stably across different ...
[139]
Aneuploidy in yeast: Segregation error or adaptation mechanism?
Aneuploidy is the loss or gain of chromosomes within a genome. It is often detrimental and has been associated with cell death and genetic disorders.
[140]
Mechanisms of oocyte aneuploidy associated with advanced ...
Trisomy cases occur at a low frequency of ∼2% among women under the age of 25 years after which the frequency increases to over 40% at ages >40 years [3,29]. ...
[141]
Down Syndrome: Practice Essentials, Background, Pathophysiology
Dec 6, 2024 · About 75% of concepti with trisomy 21 die in embryonic or fetal life. Approximately 25-30% of patients with Down syndrome die during the first ...
[142]
Chromosomal drive and the evolution of meiotic nondisjunction and ...
Trisomy has been the focus of extensive medical research, but the molecular mechanism by which nondisjunction occurs is still not understood (1, 5–8). One ...
[143]
Twenty-year trends in the prevalence of Down syndrome and other ...
Jun 20, 2012 · This study examines trends and geographical differences in total and live birth prevalence of trisomies 21, 18 and 13 with regard to increasing maternal age ...
[144]
Trisomy 13 and 18—Prevalence and mortality—A multi-registry ...
Sep 30, 2019 · The mean prevalence among LB in all registers for T13 was 0.55 (95%CI 0.38-0.72), and for T18 was 1.07 (95% CI 0.77-1.38), per 10,000 births.Missing: human | Show results with:human
[145]
Survival of Children with Trisomy 13 and Trisomy 18: A Multi-State ...
The distribution of maternal race/ethnicity was similar for both phenotypes. About 17% of the children had one or more of the CHDs listed above. Omphalocele was ...
[146]
Population monitoring of trisomy 21: problems and approaches - PMC
May 14, 2023 · The average annual prevalence of free trisomy 21 was 1: 383 among newborns or 2.61 per 1,000 live births, which is one of the highest worldwide ...
[147]
About Down Syndrome | National Down Syndrome Society (NDSS)
Trisomy 21 (Nondisjunction) Down syndrome is usually caused by an error in cell division called “nondisjunction.” Nondisjunction results in an embryo with ...
[148]
Maternal Age-Specific Rates for Trisomy 21 and Common ...
Nov 3, 2016 · The rate of T21 ranged between 2.67 per 1,000 fetuses at the age of 34 and 71.06 per 1,000 at the age of 48. The rate of common autosomal ...<|separator|>
[149]
Maternal age in the epidemiology of common autosomal trisomies
Oct 8, 2020 · The birth prevalence rate of each common autosomal trisomy generally increases with advancing maternal age and there is a substantial fetal loss rate between ...
[150]
Ethnic differences in the impact of advanced maternal age on birth ...
Aug 6, 2025 · This study explored whether ethnic differences in the impact of advanced maternal age on the risk of Down syndrome might reflect differences ...